Subscribe To
MRK / Merck: Solid Pharma Buy With Strong Upside If Keytruda Patents Extended
MRK News
By The Motley Fool
October 31, 2023
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Merck and Daiichi Sankyo just signed a multibillion-dollar drug collaboration. The pair will work to develop three medicines to eventually replace Key more_horizontal
By CNBC Television
October 27, 2023
BMO Capital upgrades Merck to 'outperform'
BMO has upgraded Merck to outperform from market perform. more_horizontal
By Investopedia
October 26, 2023
Merck's Profit Beats Estimates on Sales of Its Cancer, COVID-19 Drugs and HPV Shot
Merck (MRK) posted better-than-expected results on strong sales of its popular Keytruda cancer drug and HPV vaccine Gardasil, as well as a jump in dem more_horizontal
By Seeking Alpha
October 26, 2023
Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET Company Participants Peter Dannenbaum - Vice President, Inv more_horizontal
By Zacks Investment Research
October 26, 2023
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. more_horizontal
By Zacks Investment Research
October 26, 2023
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of more_horizontal
By CNBC
October 26, 2023
Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth
Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook. more_horizontal
By Reuters
October 26, 2023
Merck 3rd-quarter profit tops expectations on COVID pill surprise
Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primaril more_horizontal